The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 361:1809-1811 October 29, 2009 Number 18
NextNext

Hearing Improvement after Bevacizumab for Neurofibromatosis Type 2

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Plotkin, S. R.
-PubMed Citation
To the Editor: Plotkin et al. (July 23 issue)1 report a sustained tumor-volume reduction in 4 of 10 patients and a hearing response in 4 of 10 patients with neurofibromatosis type 2 after bevacizumab treatment. The authors' conclusion that tumor shrinkage and hearing improvement are effects of bevacizumab treatment is not convincing, because the study did not involve a control group. Shrinkage of a vestibular schwannoma, especially in cystic tumors in patients with neurofibromatosis type 2, can also occur during an observation period without any treatment.2 In addition, some patients who have been assigned to wait-and-scan observation show hearing improvement . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2010 Massachusetts Medical Society. All rights reserved.